GlassScriptPhysician profile
Joel L Gallagher
NPI 1427349984
$27,704.35
in general payments reported to CMS, 2019-2025
48 companies · $5,000 in 2025
The $5,000 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,890 · 2020: $2,234 · 2021: $3,530 · 2022: $4,052 · 2023: $5,584 · 2024: $4,414 · 2025: $5,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,566 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,172.84 |
| Consulting Fee | $1,565.88 |
| Education | $260.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,236.90 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $3,379.36 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,937.63 | 2019-2025 | |
| Genentech USA, INC. | $1,778.81 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,725.70 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,193.34 | 2020-2025 | Glassia, Cuvitru, Takhzyro |
| Optinose US, INC. | $1,143.47 | 2019-2025 | |
| Amgen INC. | $1,078.93 | 2021-2025 | Tezspire |
| Pfizer INC. | $892.74 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $748.88 | 2019-2025 | |
| Incyte Corporation | $661.41 | 2021-2025 | Opzelura |
| Abbvie INC. | $622.74 | 2021-2025 | |
| Csl Behring | $477.77 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Teva Pharmaceuticals USA, INC. | $352.46 | 2019-2023 | |
| Kaleo, INC. | $320.01 | 2019-2024 | Auvi-Q |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.